



Next Generation Pharmaceuticals DD • Europe
1 - 3 September 2010 • InterContinental • Vienna
www.pharmasummiteurope.com



TESTIMONIALS...

“An excellent opportunity to network with key opinion leader is drug discovery”

Jeremy Everett -

Professor and Head of Pharmaceutical, Chemical and Environmental Sciences, University of Greenwich, UK

“NGP is the perfect forum for people with real strategic issues to collaborate on key initiatives and ideas in a relaxed collegiate environment”

John Blakeley -

EVP Sales and Marketing, ERT



ANALYST PARTNER

FROST & SULLIVAN

PLATINUM SPONSOR

TACONIC

GOLD SPONSOR



PREMIUM SPONSOR

Singulex

SILVER SPONSOR



gdsinternational

BIONITY.COM

Life Science Network | Chemie.DE | Bionity.COM | ChemiEurope.COM | ChemieKarriere.NET | BioKarriere.NET | Thursday, September 09, 2010

Search for: _____ in: News [Go] [Advanced Search]

Overview | Companies | Countries | Top News

All | Business | Career | Cooperation | Finances | Laws | Manufacturing | Market | People | Politics | Products | Research | Technology

Print version | Send article | RSS feed

Pharma to Make the Private Public

09 Sep 2010 - Last week, leaders from companies like AstraZeneca, GlaxoSmithKline, Pfizer and Roche met in Vienna in a closed meeting to discuss the future of the pharma industry. Fears of layoffs at pharmaceutical companies are once again dominating the news, but could there be a less painful way to save money?

Partikelanalyse Mikrowellensysteme **NEU!**

Attendees at the Next Generation Pharmaceutical Drug Discovery Summit (hosted by GDS International) were among those leading the rumours of job cuts within the Drug Discovery Arena, but this was far from being their main focus. Despite the obvious fears and dangers, the consensus was that the only way forward was to continue looking towards the future.

Ted Torphy, Vice President & Lead, External Innovation of Johnson & Johnson made it clear that as a pharmaceutical company they were there to lend a little more rope to solution providers and to have faith in their abilities. He discussed the idea of setting up temporary partnerships to combat an innovation deficit recently noticed within pharma. Productivity within the labs has been seen to be plummeting as the focus begins to switch from diseases that are relatively common to those that are more complex or unusual.

The innovation deficit has enormous implications for the industry as a whole. Many pharmaceutical companies need to look at what they want to be doing and where they should be concentrating. They must identify the core competencies the activity will require. The pharmaceutical companies that regard R&D as a core element of their business will have to make

Evolution of business and research
Hannover 5-7 October 2010

pharmiweb.com

Search Pharmiweb.com [GO] Select a company

PHARMIWEB CHANNELS: Home | News | Resources | Events | Jobsearch | Companies | How To... | About Us | Contact Us

Pharma B2B Marketplace: The Matchmaker for the Life Science Industry. Try now!

Pharma Company Profiles: 4,000+ Biotech & Pharma Profiles Get Your Free Trial Access Today!

Pharma to Make the Private Public

Posted on: 09 Sep 10

Summary

Last week, leaders from companies like AstraZeneca, GlaxoSmithKline, Pfizer and Roche met in Vienna in a closed meeting to discuss the future of the pharma industry. Fears of layoffs at pharmaceutical companies are once again dominating the news, but could there be a less painful way to save money?

Last week, leaders from companies like AstraZeneca, GlaxoSmithKline, Pfizer and Roche met in Vienna in a closed meeting to discuss the future of the pharma industry. Fears of layoffs at pharmaceutical companies are once again dominating the news, but could there be a less painful way to save money?

Attendees at the Next Generation Pharmaceutical Drug Discovery Summit (hosted by GDS International) were among those leading the rumours of job cuts within the Drug Discovery Arena, but this was far from being their main focus. Despite the obvious fears and dangers, the consensus was that the only way forward was to continue looking towards the future.

Ted Torphy, Vice President & Lead, External Innovation of Johnson & Johnson made it clear that as a pharmaceutical company they were there to lend a little more rope to solution providers and to have faith in their abilities. He discussed the idea of setting up temporary partnerships to combat an innovation deficit recently noticed within pharma. Productivity within the labs has been seen to be plummeting as the focus begins to switch from diseases that are relatively common to those that are more complex or unusual.

"The innovation deficit has enormous implications for the industry as a whole. Many pharmaceutical companies need to look at what they want to be doing and where they should be concentrating. They must identify the core competencies the activity will require. The pharmaceutical companies that regard R&D as a core element of their business will have to make fundamental alterations in the way they work."

Pharma B2B Marketplace: Learn from toptech experts! Take a look at our course calendar

Pharma Consulting: Consulting services for assay systems considering GLP/GMP! www.bioss.com/Pharma_B2B

£75K+ Sales Jobs: Thousands of UK Sales Jobs Search & Apply Online Today! www.TheJobsites.co.uk/

Thermo SCIENTIFIC *Moving Science*

SEARCH BY KEYWORDS | BY ARTICLES | BY CATEGORY | BY COMPANY | SEARCH ADVANCED MENU

ALFA AEMULSION
HOMOGENISING MIXERS

ci
CI Electronics Ltd
CALL TODAY
+44(0)1603
708833

Thermal Detection
PRODUCTS

Pharmaglobe

Showing article 20 of 23 | < | > | Print | Home >

Next Generation Pharmaceutical Drug Discovery Summit

Last week, leaders from companies like AstraZeneca, GlaxoSmithKline, Pfizer and Roche met in Vienna in a closed meeting to discuss the future of the pharma industry. Fears of layoffs at pharmaceutical companies are once again dominating the news, but could there be a less painful way to save money?

Attendees at the Next Generation Pharmaceutical Drug Discovery Summit (hosted by QDS International) were among those leading the numbers of job cuts within the Drug Discovery Arena, but this was far from being their main focus. Despite the obvious news and dangers, the consensus view that the only way forward was to continue looking towards the future.

Thed Forth, vice President & Lead, External Innovation at Johnson & Johnson made it clear that as a pharmaceutical company they view there to lend a little more rope to solution providers and to have faith in their abilities. He discussed the idea of setting up temporary partnerships to combat an innovation deficit recently noticed within pharma. Productivity within the area has been seen to be plummeting as the focus begins to divert from diseases that are relatively common to those that are more complex or unusual.

He said: "The innovation deficit has enormous implications for the industry as a whole. Many pharmaceutical companies need to look at what they want to be doing and where they should be concentrating. They must identify the core competencies the activity will require. The pharmaceutical companies that regard R&D as a core element of their business will have to make fundamental alterations in the way they operate."

One suggestion made is that the industry should become more intensive and seek to reducing its R&D costs. Private companies who conventionally undertake pharmaceutical research in a traditionally equity stringent measures to protect their research results as private intellectual property. If and they have achieved a remarkable success. A by-product of this is an inability to share their research results with each other, sometimes even within a single company. Pharmaceutical researchers tend to be consumers rather than suppliers. Consequently, commercial competitors are hindered from access to important discoveries as well as an effective research history. So the consensus at the NGP-DD Summit was that a need to the 'P-Shed' and the recently experienced innovation deficit.



DRUG DISCOVERY TODAY.com

Epilepsy and Depressive Disorders
An Epilepsy & Behavior conference
12-13 September 2010 The Westin Chicago River North Hotel, Chicago, USA

REGISTER NOW

Members' Login

Email Address:

Password:

LOGIN

Forgotten login?

Not a member?

Podcasts/ Newscasts

Webinars

Downloads/ White Papers

News

Key Research Articles

Biotechnology

Companies and People

Drug Metabolism

Drug Trials

Informatics

Medical Chemistry

Novel Technologies

Pharmacology/ Therapeutics

Regulatory

Target Identification/ Validation

Events & Training

News

Pharma 'HTS' the mark with screening

28 July 2010

In May, it was announced that new research into stem cell reprogramming would reduce the need for animal testing; now, we are really beginning to see the benefits of this groundbreaking science.

Huge amounts of money are invested in drug discovery, and a considerable problem for the industry is investing in drugs that might not make it onto the market. Europe has always been perceived as trailing behind the USA in drug discovery: within the pharmaceutical industry, but with the biotechnology revolution, they are catching up and becoming a driving force within the global industry.

Pfizer announced recently that they plan to roll out a hit identification and screening file strategy, which will offer a flexible strategy for hit identification while adopting a more reliable and efficient screening process. High-throughput screening (HTS) has grown rapidly over the past ten years, and Pfizer themselves have noted the huge advances in both detection technology and laboratory automation.

Pfizer believes that both big Pharma and smaller companies can implement HTS. Implementing HTS can remove indecision over which compounds will be profiles; many smaller companies agonize over the costs of conventional profiling, sometimes choosing only 10-20 compounds, but the removes other possibilities before true research begins.

Pfizer, and other members of the Next Generation Pharmaceutical Europe Drug Discovery committee, wish to discuss how to implement large-scale profiling at a lower cost, while maintaining biological, technological, and scientific advancement.

Key to discussions will be representatives from AstraZeneca (Doran Wernberg, VP Discovery Information), Bayer Schering Pharma (Andreas Busch, Head of

DRUG DISCOVERY TODAY

Related Stories

RIND calls on industry to invest in treatments for hearing loss

Hearing loss charity, RIND, is traveling to Chicago to launch a special issue of Drug Discovery Today at BIO International, the world's largest biotechnology conference. RIND will be exhibiting at booth number 4707. Produced in association with RIND and Fight for Sight, the publication highlights the exciting progress being made in developing treatments for hearing and vision loss.

BioVales back with hot topics for 2010

BioVales will return in 2010 to showcase the bioscience sector in Vales to an international,

Epilepsy and Depressive Disorders

An Epilepsy & Behavior conference

12-13 September 2010

The Westin Chicago River North Hotel, Chicago, USA

DRUG DISCOVERY TODAY

Sign up for your **FREE** digital edition of Drug Discovery Today

Epilepsy and

european pharmaceutical review

Home Magazines Events Advertising Directory Join us News Contact us

Innovative Microplate Readers
For Life Science and HTS

Search website

Click here to login / logout >>

[Join us on LinkedIn](#) |
 [Subscribe to RSS feeds](#) |
 [Join us on LinkedIn](#) |
 [Follow us on Twitter](#)

mid IR fibre optic probes for reaction monitoring



[FIBRE PHOTONICS NEW WEB SITE](#)



[European Pharmaceutical Regulatory Law II Infographic](#)



[learn more about THE NEW HEALTH](#)



[learn more about THE NEW HEALTH](#)

You are here: [Home](#) > [News](#) > [Industry news](#) > Pharma 'HTS' the Mark with Screening

Pharma 'HTS' the Mark with Screening

PUBLICATION DATE: 21 JULY 2010
AUTHOR: NG ONLINE NEWS

TAGGED WITH: [ANDREAS BUSCH](#) [ASTRAZENECA](#) [BAYER SCHERING PHARMA](#) [GLAXOSMITHKLINE](#) [GORAN WEINBERG](#) [HTS \(HIGH THROUGHPUT SCREENING\)](#) [JOHJ MATHIAS](#) [NOVARTIS](#) [OLIVIER GRENET](#) [PFIZER](#) [TINO ROSSI](#)

Back in May, it was announced that new stem cell research would reduce the need for animal testing. Now, we are really beginning to see the benefits of groundbreaking science that is not reliant on out dated methods of testing. The proposal was that by reprogramming powerful stem cells from adult tissue, we could look towards a future without animal testing.

It is understood that huge amounts of money have been invested into drug discovery and the biggest problem faced by the industry is investing in drugs which may not make it onto the market. Europe has always been seen to trail behind the US when discussing drug discovery within the pharmaceutical industry, but with the biotechnology revolution they have begun to catch and becoming a driving force within the global industry.

The NGP EU committee has been celebrating the success of their pioneering roles in genome sequencing and the development of proteomic. Pfizer has recently announced to the NGP Drug Discovery committee that they plan to roll out a hit identification and screening file strategy. The process will offer a new flexible strategy for hit identification while sculpting a more reliable and efficient screening process.

Hit-throughput screening (HTS) has grown rapidly over the last ten years and Pfizer themselves noted the huge advances in both detection technology and laboratory automation. Pfizer believe that not only big Pharma but also smaller companies can implement HTS as well. By implementing HTS, it can remove the indecision over which compounds will be profiles, many smaller companies agonize over the costs of conventional profiling sometimes only choosing between 10 and 20 compounds, this already removes other possibilities before true research can really begin. Pfizer among other members of the NGP EU Drug Discovery committee wish to discuss how they wish to implement large scale profiling at a lower cost while maintaining the incredible biological, technological, and scientific advancements they are already demonstrating globally.

GSK have also joined Pfizer recently in encouraging the implementation of HTS. "We are now at a stage where we can exploit the benefits of cutting edge technology for increased quality, performance and capabilities. We also have

[Company directory listings](#)

[- Accessory list](#)

learn more about THE NEW HEALTH



Home
About
Contact
Services
BioCareers
Archives

Topics

- BioBusiness
- BioCareers
- BioEducation
- BioJob Tools
- BioJobBuzz
- BioTraining
- General Job Stuff
- Healthcare Informatics
- Ideas and Indulgences
- Job Surfing
- Odds N Ends
- Rants and Raves
- Social Media
- Archives

Follow Me On Twitter

Join Me... @BioCrowd!

BioCareers PROVIDED BY BIOCROWD

BioJobBlog



Home > BioBusiness > "Hit" Throughput Screening (HTS)???

Posted on July 21, 2010 by BioJobBlogger

"Hit" Throughput Screening (HTS)???



○ = Positive hits

No, this isn't a typo! My colleagues at Meet the Boss sent me a press release today about efforts underway at Pfizer and GlaxoSmithKline to redefine HTS to mean "hit" throughput screening rather than high throughput screening. As many of you may know, high throughput screening which began in the mid 1990s was supposed to revolutionize drug discovery and development—it did not! Nevertheless, after almost 15 years of refinement it appears that the technology may be paying off and can be used as an adjunctive tool to expedite and lower the cost of small molecule and protein-based drug discovery. While I don't know much about this emerging technology, the press release presented below suggests that a meeting about HTS may be in the works.

The growth of HTS (Hit-throughput screening)

It is understood that huge amounts of money have been invested into drug discovery and the biggest problem faced by the industry is investing in drugs which may not make it onto the market. Europe has always been seen to trail behind the US when discussing drug discovery within the pharmaceutical industry, but with the biotechnology revolution

Email This

Print

Comments

Trackbacks

Share Link

BIONITY.COM

Life Science Network | Chemie.DE | Bionity.COM | ChemieEurope.COM | Chemiekamera.NET | Biokamera.NET | Thursday, July 22, 2010

Companies & Products
 Buyer's Guide
 Product Gallery
 Catalogues
 Software
 Biotech Books
 Antibodies
 Market Overview

News Center
 Current News
 Newsletter
 Articles

RSS-Feeds
 Information Retrieval
 Life Science Encyclopedia

Job & Career
 Events

Toolbox
 Specialised Dictionaries
 Unit Conversion
 Molecular Mass Calculator

Newsletter Subscription
 Your e-mail:
 @email.com



About Bionity.COM
 The Company
 Products & Solutions
 Advertising opportunities
 Press
 Jobs and Careers
 Advertising rates
 References
 Contact
 Imprint
 Data protection policy

Current News
 Search for: in: News [Advanced search](#)

Overview | Companies | Countries | Top News
 All | Business | Career | Cooperation | Finances | Laws | Manufacturing | Market | People | Politics | Products | Research | Technology


Print version | PDF version | Send article | RSS feed

Pharma 'HTS' the Mark with Screening
 22 Jul 2010 - Back in May, it was announced that new stem cell research would reduce the need for animal testing. Now, we are really beginning to see the benefits of groundbreaking science that is not reliant on out dated methods of testing. The proposal was that by reprogramming powerful stem cells from adult tissue, we could look towards a future without animal testing.

Anzeige   It is understood that huge amounts of money have been invested into drug discovery and the biggest problem faced by the industry is investing in drugs which may not make it onto the market. Europe has always been seen to trail behind the US when discussing drug discovery within the pharmaceutical industry, but with the biotechnology revolution they have begun to catch and becoming a driving force within the global industry.

The NCP EU committee has been celebrating the success of their pioneering roles in genome sequencing and the development of proteomic. Pfizer has recently announced to the NCP Drug Discovery committee that they plan to roll out a hit identification and screening file strategy. The process will offer a new flexible strategy for hit identification while sculpting a more reliable and efficient screening process.

Hit-throughput screening (HTS) has grown rapidly over the last ten years and Pfizer themselves noted the huge advances in both detection technology and laboratory automation. Pfizer believe that not only big Pharma but also smaller companies can implement HTS as well. By implementing HTS, it can remove the indecision over which compounds will be profiles, many smaller companies agonize over the costs of conventional profiling sometimes only choosing between 10 and 20 compounds; this already removes other possibilities before true research can really begin. Pfizer among other members of the NCP EU Drug Discovery committee wish to discuss how they wish to implement large scale profiling at a lower cost while maintaining the incredible biological, technological, and scientific advancements they are already demonstrating globally.

10 years
CHEMIE.DE


the pharma letter

HOME | 30 DAY PREMIUM TRIAL | PHARMACEUTICALS | BIOTECHNOLOGY | GENERICS | EVENTS | COMPANIES | DRUGS | SUBSCRIBE

Keywords: Research, Partnerships, Intellectual property, GDS, Johnson & Johnson

Pharma should make "the private public" to boost research, industry execs conclude
 Article | 7 September 2010

Print This | Share This

Last week, executives from companies including AstraZeneca, GlaxoSmithKline, Johnson & Johnson, Pfizer and Roche met in Vienna, Austria, in a closed meeting to discuss the future of the pharmaceutical industry. Fears of layoffs at drugmakers are once again dominating the news - notably last week with Roche's announcement of its "operational excellence" initiative (The Pharma Letter September 6), but could there be a less painful way to save money?

Attendees at the Next Generation Pharmaceutical Drug Discovery Summit (hosted by GDS International) were among those leading the rumors of job cuts within the drug discovery arena, but this was far from being their main focus. Despite the obvious fears and dangers, the consensus was that the only way forward was to continue looking towards the future.

Enjoying this article? Have the leading Biopharma news & analysis delivered daily on email by signing up for our FREE email newsletter here.

Temporary partnerships mooted


Related Articles


- Swiss firm Helsinn opens new \$16.7 million R&D center in Ireland | 7 September 2010
- Tough road ahead for some generics after USA's Federal Circuit Patent Use Code decisions | 7 September 2010
- Israel relaxes restrictions on medical marijuana; scientists develop new HIV/AIDS treatment | 7 September 2010
- Abbott Labs gives up on vaccines unit sale, as no adequate bidders in sight; heart risks reported with obesity drug Meridia | 6 September 2010
- India's Natco challenges Celgene's Revlimid patent in USA; new CFO named | 6 September 2010


Latest Articles

- GlaxoSmithKline's Avandia still available in UK, despite MHRA call for its suspension | 7 September 2010
- Silence Thera receives takeover approach from unnamed drug firm | 7 September 2010

the pharma letter
 30 day Premium Trial with daily email newsletter
 Worth £60!

Follow us... on twitter 

Get our RSS feed 

Events Calendar 



- Home
- New On This Site
- Products & Services
- Company A-Z
- Industry Projects
- Features
- White Papers
- Jobs & Careers
- Industry News**
- Gallery
- Events & Exhibitions
- Newsletter Sign-Up
- Advertise With Us
- About Us
- Client Area

Home » Industry News » Industry News Archives » J&J Chief Calls for Innovation

J&J Chief Calls for Innovation

07 September 2010

Email Article Print

Ted Torphy, vice-president of Johnson & Johnson has called for increased innovation to drive the pharmaceutical industry forward.

According to the J&J chief at present, conventional research employs stringent measures to protect results as intellectual property until a marketable compound is achieved. As a result, companies are unable to share findings with each other, hindering drug development.

Speaking at the next-generation pharmaceutical drug discovery summit in Vienna, he proposed the idea of "temporary partnerships" to combat an innovation deficit, which is causing lab productivity to fall.

"The innovation deficit has enormous implications for the industry as a whole. Many pharmaceutical companies need to look at what they want to be doing and where they should be concentrating," he said.

This view was shared at the summit by representatives of AstraZeneca and GlaxoSmithKline, which also called for open collaborations and the sharing of intelligent property.

Post to: [Delicious](#) [Digg](#) [reddit](#) [Facebook](#) [StumbleUpon](#)

MyTrainingExpert

www.mytrainingexpert.com

- ✔ Significant savings
- ✔ Impartial advice



Newsletter Sign-Up

For all the latest news in the pharmaceutical industry, sign up here

Email address

Subscribe



pharmaceutical-technology.com is a product of Net Resources International. Copyright 2010 Net Resources International, a trading division of SPG Media Limited.



Pharma 'HTS' the Mark with Screening

July 2010: Back in May, it was announced that new stem cell research would reduce the need for animal testing. Now, we are really beginning to see the benefits of groundbreaking science that is not reliant on out dated methods of testing. The proposal was that by reprogramming powerful stem cells from adult tissue, we could look towards a future without animal testing.

It is understood that huge amounts of money have been invested into drug discovery and the biggest problem faced by the industry is investing in drugs which may not make it onto the market. Europe has always been seen to trail behind the US when discussing drug discovery within the pharmaceutical industry, but with the biotechnology revolution they have begun to catch and becoming a driving force within the global industry.

The NGP EU committee has been celebrating the success of their pioneering roles in genome sequencing and the development of proteomic. Pfizer has recently announced to the NGP Drug Discovery committee that they plan to roll out a hit identification and screening file strategy. The process will offer a new flexible strategy for hit identification while sculpting a more reliable and efficient screening process.

Hit-throughput screening (HTS) has grown rapidly over the last ten years and Pfizer themselves noted the huge advances in both detection technology and laboratory automation. Pfizer believe that not only big Pharma but also smaller companies can implement HTS as well. By implementing HTS, it can remove the indecision over which compounds will be profiles, many smaller companies agonize over the costs of conventional profiling sometimes only choosing between 10 and 20 compounds, this already removes other possibilities before true research can really begin. Pfizer among other members of the NGP EU Drug Discovery committee wish to discuss how they wish to implement large scale profiling at a lower cost, while maintaining the incredible biological, technological, and scientific advancements they are already demonstrating globally.

GSK have also joined Pfizer recently in encouraging the implementation of HTS. "We are now at a stage where we can exploit the benefits of cutting edge technology for increased quality, performance and capabilities. We also have the option to supply the same number of compounds, with the same level of quality at an affordable price".

Key to discussions will be representatives from AstraZeneca - Goran Wennberg, VP Discovery Information, Bayer Schering Pharma - Andreas Busch, Head of Global Drug Discovery & Member of the Board, Novartis - Olivier Grenet, Group Head of Genome Biology, GlaxoSmithKline - Tino Rossi, VP of PreClinical Drug Discovery & Enabling Technologies and Pfizer - John Matthias, Head of High Through Put Screening all determined to firmly place Europe as the Drug Discovery capital.

The discovery and implementation of HTS not only offers an opportunity to smaller Pharma companies but also the consumer. If research and quality is increased and cost decreased this in turn will be passed onto the consumer.

Contact: Emma Naylor
Tel: 01244 004 052


Biotechnology Management
Online masters program, 13 months. Top-ranked IE Business School
[www.ie.edu/SchoolBio](#)

Pharma B2B Marketplace
The Matchmaker for the pharmaceutical industry. Try now!
[www.pharmab2b.com](#)

Medical Volunteers Wanted
Register For The Latest Medical Trials. Financial Reimbursement!
[DrugTrial.co.uk/Volunteer](#)

Clinical Research Jobs
For Clinical Operations and R&D Jobs Apply Now
[@Clinical.co.uk/clinicaljobs](#)

Ads by Google



- Home
- News
- White Papers
- Latest events
- Buyers' Guide
- Media kit
- List Rental
- Magazine issues
- Submit editorial
- Outsourcing Awards
- Subscribe
- Via TV
- Careers
- Market watch



Pharma 'HTS' the Mark with Screening

Back in May, it was announced that new stem cell research would reduce the need for animal testing. Now, we are really beginning to see the benefits of groundbreaking science that is not reliant on outdated methods of testing. The proposal was that by reprogramming powerful stem cells from adult tissue, we could look towards a future without animal testing.

Huge amounts of money have been invested into drug discovery and the biggest problem faced by the industry is investing in drugs that may not make it onto the market. Europe has always been seen to trail behind the US when discussing drug discovery within the pharmaceutical industry, but with the biotechnology revolution they have started to catch up and become a driving force within the global industry.

The NCP EU committee has been celebrating the success of their pioneering roles in genome sequencing and the development of proteomic. Pfizer has recently announced the NCP Drug Discovery committee that they plan to roll out a hit identification and screening file strategy. The process will offer a new flexible strategy for hit identification while sculpting a more reliable and efficient screening process.

Hit-throughput screening (HTS) has grown rapidly during the last 10 years, and Pfizer has noted the huge advances in both detection technology and laboratory automation. Pfizer believes that both Big Pharma and smaller companies can implement HTS as well. By implementing HTS, companies can remove the indecision regarding which compounds will be profiles. Because of the costs associated with conventional profiling, many smaller companies sometimes only choose between 10 and 20 compounds, which removes other possibilities before true research can really begin. Pfizer among other members of the NCP EU Drug Discovery committee wants to discuss how they wish to implement large-scale profiling at a lower cost, whilst maintaining the biological, technological and scientific advancements they are already demonstrating globally.

GSK has also joined Pfizer recently in encouraging the implementation of HTS. Robert Hertzberg, VP Screening and Compound Profiling, at GSK, said: "We are now at a stage where we can exploit the benefits of cutting-edge technology for increased quality, performance and capabilities. We also have the option to supply the same number of compounds, with the same level of quality at an affordable price."

Key to the discussions will be representatives from AstraZeneca (Goran Wennberg, VP Discovery Information), Bayer Schering Pharma (Andreas Busch, Head of Global Drug Discovery & Member of the

- Podcasts/ Newcasts
- Webinars
- Downloads/ White Papers
- News
- Key Research Articles
- Biotherapeutics
- Companies and People
- Drug Metabolism
- Drug Trials
- Informatics
- Medicinal Chemistry
- Novel Technologies
- Pharmacology/ Therapeutics
- Regulatory
- Target Identification/ Validation
- Events & Training



Epilepsy

News

The BIG retreat

07 July 2010

Some of pharmaceutical's big boys, for example Pfizer, have faced well-documented challenges over the last 12 months. The industry is only too aware of this and understands that now is the time to look at new processes and a change in the way they have traditionally done business.

Globally, the pharmaceutical industry is witnessing rapid advancements in processes and technological developments. Automation is emerging as an integral part of nearly all manufacturing processes and pharmaceutical big wigs are ready to invest in the future. Due to the implementation of regulatory norms and spiraling costs, pharmaceutical companies have been opting to outsource their manufacturing processes to contract manufacturing organizations in order to improve on efficiency and productivity. Countries such as Brazil, Ukraine, Mexico, Peru, China and India have taken full advantage of the need for lower manufacturing costs and have also a boost in manufacturing growth, but this in itself has its own drawbacks.

Eighty percent of the drugs entering the U.S. and Western European markets in 2008 were tested overseas, but the FDA says they only inspect 0.7 percent of foreign clinical trial sites, according to a new report from the Health and Human Services Inspector General ([http://www.hhs.gov/ohrt/070710/070710report.html](#)). Critics say this makes it more difficult for regulators to verify clinical results. The report notes a growth in trials in places like India, China, Eastern Europe and South America. For example, the report cites particularly large trials in India.

Rep. Rosa DeLauro (D-Conn.) called the report "very frightening" and said, "The

DRUG DISCOVERY
TODAY

Sign up for your **FREE**
digital edition of
Drug Discovery Today



Next generation pharmaceutical

Related Stories

Innovative Medicines Initiative reveals new research topics and a new Executive Director

Innovative Medicines Initiative, the public-private partnership between the European Commission and the European pharmaceutical industry (represented by EFPIA), today made its first major announcement of the success of the collaboration.

Marine mirzobek, creation create issues in

Members' Login

Email Address

Password

LOGIN

Forgotten login?

Not a member?

Epilepsy and Depressive Disorders



An Epilepsy & Behavior conference

12-13
September
2010

The Westin Chicago
River North Hotel,
Chicago, USA